North & North · Research
Peptide Human Trials
Checked one by one against the registry
For years the honest answer about the research peptides here was that almost no controlled human work existed. That changed in 2026. 4 trials are recruiting right now, most of them placebo controlled. Two of the 6 study preparations this catalog does not sell, and both are marked.
The pattern worth noticing
Four Compounds, One Sponsor, One Month
BPC-157, GHK-Cu, MOTS-c and TB-500 all entered placebo controlled Phase 2 within days of each other.
These four had almost no controlled human work behind them, and then in February 2026 the same sponsor opened a trial for each. That is not four separate coincidences. It is somebody deciding this family of compounds was worth testing properly, all at once, and it is the clearest sign yet that the field is moving from preclinical work into people. None of them has reported anything, and this page will say so until they do.
The register
The Register
Listed by compound, with status exactly as the registry states it, including the one that was terminated. None of these trials uses North & North material, and none is run by North & North. Two are not the same preparation this catalog sells, and are labelled where they appear: the NL005 record studies a recombinant Thymosin Beta 4 rather than TB-500, and the CJC-1295 record used the long acting DAC form rather than the No DAC form. Neither is attached to a product page, because findings on one form do not carry to the other.
Scope: the research peptides in this catalog, BPC-157, GHK-Cu, MOTS-c, TB-500 and CJC-1295. Tirzepatide and Retatrutide are deliberately not here. They are also sold on this site, but they carry hundreds of registered trials between them and are mainstream pharmaceutical subjects, so listing a handful would misrepresent the field rather than describe it.
- BPC-157Recruiting
BPC 157 for Acute Hamstring Muscle Strain Repair
Hudson BiotechPhase 2120 participantsStarted February 2026Placebo controlledThe first placebo controlled human trial of BPC-157 on the injury type it is most discussed for.
- GHK-CuRecruiting
Topical GHK-Cu Gel for Acute Skin Wound Healing
Hudson BiotechPhase 260 participantsStarted February 2026Placebo controlledEach participant carries both the gel and a vehicle control, so they act as their own comparison.
- MOTS-cRecruiting
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight
Hudson BiotechPhase 2120 participantsStarted February 2026Placebo controlledThe metabolic question MOTS-c was discovered around, asked in people for the first time.
- TB-500Recruiting
TB-500 for Cardiovascular Biomarkers in Stable Atherosclerotic Cardiovascular Disease
Hudson BiotechPhase 1 and 280 participantsStarted February 2026Placebo controlledNamed TB-500 in the registry itself, which is rare: most records use the parent protein name.
- Recombinant Human Thymosin Beta 4 (NL005)Not yet recruiting
Recombinant Human Thymosin Beta 4 for Acute Myocardial Infarction
Beijing Northland BiotechPhase 2189 participantsStarted May 2026Placebo controlledA different preparation of the same parent protein, listed because it is the largest of these and is often confused for a TB-500 trial.
- CJC-1295 (DAC form)Terminated
A Study to Evaluate CJC-1295 in Patients With Visceral Obesity
ConjuChemPhase 20 participantsStarted December 2005The only CJC-1295 trial ever registered, and it was terminated. It used the long acting DAC form rather than the No DAC form sold here, so it says nothing about that one either way.
Every record above was checked directly against ClinicalTrials.gov by its identifier on September 2026. Statuses change, so the registry is always the authority. If you find one of these out of date, the link beside it goes straight to the source.
Common questions
Questions People Ask
Is North & North material used in these trials?
No. Every trial listed here is run by its own sponsor using its own material, and North & North has no involvement in any of them. Two of the six do not even study the same preparation this catalog sells: the NL005 record is a recombinant Thymosin Beta 4, and the CJC-1295 record used the long acting DAC form. Both are marked as such.
Why did so many of these start at the same time?
Four of them share a sponsor, Hudson Biotech, and nearly a start date in February 2026. That is the single most interesting fact on this page: BPC-157, GHK-Cu, MOTS-c and TB-500 entered placebo controlled Phase 2 together, having had almost no controlled human work before.
Have any of these reported results?
None. Every active trial here is still recruiting or has not opened. Anyone quoting an outcome from one of them is quoting something that has not been published.
Why is a terminated trial on the list?
Because leaving it out would make this an advert. The only CJC-1295 trial ever registered was terminated in 2005, and it studied the long acting DAC form rather than the No DAC form sold here. So the honest answer for No DAC is that no registered trial has ever studied it.
How current is this page?
Every record here was checked directly against the ClinicalTrials.gov registry by its identifier, and the date it was last checked is shown at the foot of the list. Statuses change, so the registry itself is always the authority.
Go deeper
Research on Each Compound
Catalog access
Create a Free Account
Create a quick and easy free account to shop every compound in the library and other peptides.
Free to create. You will verify your email address before the catalog opens.